The most recent report in advanced NSCLC näive patients and in patients previously treated with 1st/2nd generation TKIs receiving osimertinib indicates that the most common EGFR-independent resistance mutation affects the TP53 gene [89]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.